Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

XORTX Therapeutics Inc XRTX


Primary Symbol: V.XRTX

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.


TSXV:XRTX - Post by User

Post by Iseneschalon Feb 28, 2024 2:30pm
69 Views
Post# 35904532

XRTX...U may want to re-read the P.O terms ; )

XRTX...U may want to re-read the P.O terms ; )

XORTX's initial offering closing raises $2.47-million

2024-02-15 07:47 ET - News Release

Mr. Allen Davidoff reports

XORTX RAISES $2.5 MILLION UNDER PROSPECTUS SUPPLEMENT AND CONCURRENT PRIVATE PLACEMENT FOR THE OFFERING OF RIGHTS

XORTX Therapeutics Inc. has made an initial closing for gross proceeds of $2,474,301 under its previously announced offering, including $690,000 in a concurrent private placement of the company in connection with international subscribers.

The initial closing of the non-brokered offering comprised 824,767 common share units at $3.00 per common share unit, with each common share unit consisting of one common share, no par value, and one warrant to purchase one common share at $4.50 per common share for a period of two years for aggregate gross proceeds of $2,474,301, prior to deducting offering expenses. The common shares and warrants contained in the common share units are immediately separable upon issuance. The warrants have an initial exercise price of $4.50 per share, will be immediately exercisable, and may be exercised for two years from the date of issuance, provided, however that, if, the common shares on the TSX Venture Exchange trade at greater than $6.00 for 10 or more consecutive trading days, the warrants will be accelerated and the warrants will expire on the 30th business day following the date of such notice.

In connection with the offering, the company paid finder's fees of $122,208, representing a 5-per-cent finder's fee on certain subscriptions in the offering to qualified finders.

The company anticipates that a second tranche closing under the same terms of the offering will close on or about Feb. 20, 2024.

<< Previous
Bullboard Posts
Next >>